as of 01-15-2026 12:48pm EST
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 28.6M | IPO Year: | 2020 |
| Target Price: | $34.50 | AVG Volume (30 days): | 85.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $20.00 | Next Earning Date: | 03-03-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Avg Cost/Share
$18.44
Shares
2,062
Total Value
$38,022.04
Owned After
5,402
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$18.44
Shares
4,076
Total Value
$75,158.99
Owned After
6,524
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Borthwick Kathleen | PASG | CFO | Jan 8, 2026 | Sell | $18.44 | 2,062 | $38,022.04 | 5,402 | |
| Chou William | PASG | PRESIDENT AND CEO | Jan 8, 2026 | Sell | $18.44 | 4,076 | $75,158.99 | 6,524 |
See how PASG stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PASG Passage Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.